The accuracy of 18FDG-PET in the early diagnosis of Alzheimer's disease dementia and other dementias in people with MCI

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 7, 2013, Pages

  Vacante, Marco ^a   Smailagic, Nadja ^b   Sachpekidis, Christos ^c   Hyde, Chris ^d   Martin, Steven ^b   Ukoumunne, Obioha ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL PROTOCOL; DEMENTIA; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE QUALITY; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

EID: 85019982677     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010632     Document Type: Article

References (62)

1. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia 2011; Vol. 7, issue 3:270-9. [: 1552-5260]
2. Anchisi D, Borroni B, Franceschi M, Kerrouche N, Kalbe E, Beuthien-Beumann B, et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Archives of Neurology 2005;62:1728-33.
3. American Psychiatric Association. Diagnostic and Statistic Manual of Mental Disorders (DSM-III-R). 3rd Edition. Washington DC: American Psychiatric Association, 1987.
4. American Psychiatric Association. Diagnostic and Statistic Manual of Mental Disorders (DSM-IV-TR). 4th Edition. Washington DC: American Psychiatric Association, 1994.
5. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011;377(9770):1019-31. [PUBMED: 21371747]
6. Beckett LA, Harvey DJ, Gamst A, Donohue M, Kornak J, Zhang H, et al. The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimer's and Dementia 2010; Vol. 6, issue 3:257-64. [: 1552-5260]
7. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: ]
8. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Family Practice 2004;21(1):4-10. [: 0263-2136]
9. Bossuyt PM, Leeflang MM. Developing criteria for including studies. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Chapter 6. Version 0.4 2008.
10. Bourne J. Improving services and support for people with dementia. National Audit Office 2007.
11. Boxer AL, Miller BL. Clinical features of frontotemporal dementia. Alzheimer Disease and& Associated Disorders 2005; Vol. 19:S3-6. [: 0893-0341]
12. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica 1991; Vol. 82, issue 4:239-59. [: 0001-6322]
13. Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. International Psychogeriatrics 2004; Vol. 16, issue 2:129-40. [: 1041-6102]
14. Chen K, Langbaum J, Fleisher AS, Ayutyanont N, Reschke C, Lee W, et al. Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative. Neuroimage 2010; Vol. 51, issue 2:654-64. [: 1053-8119]
15. Chételat G, Desgranges B, De la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology 2003;60:1374-7.
16. Duara R, Grady C, Haxby J, Sundaram M, Cutler N, Heston L, et al. Positron emission tomography in Alzheimer's disease. Neurology 1986; Vol. 36, issue 7:879. [: 0028-3878]
17. Dubois B, Feldman HH, Jacova C, Cummings JL, DeKosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer's disease: a new lexicon. The Lancet Neurology 2010; Vol. 9, issue 11:1118-27. [: 1474-4422]
18. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. The Lancet 2005; Vol. 366, issue 9503:2112-7. [: 0140-6736]
19. Geslani DM, Tierney MC, Herrmann N, Szalai JP. Mild cognitive impairment: an operational definition and its conversion rate to Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2005; Vol. 19, issue 5-6:383-9. [: 1420-8008]
20. Glanville JM, Crawford F, Dozier M, Lowson P. Handsearching for reports of diagnostic test accuracy studies: adding to the evidence base. Joint Cochrane and Campbell Colloquium; 2010 Oct 18-22. Keystone, Colorado, USA: Cochrane Database of Systematic Reviews, Supplement 2010; Suppl (CD000002): 48., 2010.
21. Greenhalgh T, Peacock R. Effectiveness and efficiency of search methods in systematic reviews of complex evidence: audit of primary sources. BMJ 2005; Vol. 331, issue 7524:1064-5. [: 0959-8138]
22. Haxby JV, Grady CL, Duara R, Schlageter N, Berg G, Rapoport SI. Neocortical metabolic abnormalities precede nonmemory cognitive defects in early Alzheimer's-type dementia. Archives of Neurology 1986; Vol. 43, issue 9:882.
23. Herholz K, Salmon E, Perani D, Baron J, Holthoff V, Frölich L, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002; Vol. 17, issue 1:302-16. [: 1053-8119]
24. World Health Organization. Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10). available from apps.who.int/classifications/icd10/browse/2010/en. International (accessed 16th December 2012) 2010.
25. Knottnerus JA, Van Weel C, Muris JWM. Evaluation of diagnostic procedures. BMJ 2002; Vol. 324, issue 7335:477-80. [: 0959-8138]
26. Leeflang MMG, Deeks JJ, Gatsonis C, Bossuyt PMM. Systematic reviews of diagnostic test accuracy. Annals of Internal Medicine 2008; Vol. 149, issue 12:889.
27. Lucignani G, Frost J. Neurochemical imaging with emission tomography: Clinical applications. Diagnostic nuclear medicine 2006:7-37.
28. The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry 1994;57(4):416-8.
29. Macaskill P, Gatsonis C, Deeks J, Harbord R, Takwoingi Y. Chapter 10: Analysing and presenting results. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy 2010; Vol. 1.
30. Matthews FE, Stephan B, McKeith IG, Bond J, Brayne C. Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?. Journal of the American Geriatrics Society 2008; Vol. 56, issue 8:1424-33. [: 1532-5415]
31. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302(4):385-93.
32. McKeith I, Galasko D, Kosaka K, Perry E, Dickson D, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) Report of the consortium on DLB international workshop. Neurology 1996; Vol. 47, issue 5:1113-24. [: 0028-3878]
33. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Journal of Alzheimer's Disease 2006; Vol. 9:417-23. [: 1387-2877]
34. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; Vol. 34, issue 7:939. [: 0028-3878]
35. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia 2011; Vol. 7, issue 3:263-9. [: 1552-5260]
36. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: ]
37. Morbelli S, Piccardo A, Villavecchia G, Dessi B, Brugnolo A, Piccini A, et al. Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study. European Journal of Nuclear Medicine and Molecular Imaging 2010; Vol. 37, issue 1:36-45. [: 1619-7070]
38. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology; Neurology 1993. [: 1526-632X]
39. Morris JC, Price JL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. Journal of Molecular Neuroscience 2001; Vol. 17, issue 2:101-18. [: 0895-8696]
40. Mosconi L. FDG PET in the evaluation of mild cognitive impairment and early dementia. In: Silverman D editor(s). PET in the evaluation of Alzheimer's Disease and related disorders. Springer, 2009:49-65. [: 0387764194]
41. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; Vol. 51, issue 6:1546-54. [: 0028-3878]
42. Nitrini R, Buchpiguel C, Caramelli P, Bahia V, Mathias S, Nascimento C, et al. SPECT in Alzheimer's disease: features associated with bilateral parietotemporal hypoperfusion. Acta Neurologica Scandinavica 2000; Vol. 101, issue 3:172-6. [: 1600-0404]
43. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Aß immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004; Vol. 43, issue 3:321-32.
44. Okello A, Edison P, Archer H, Turkheimer F, Kennedy J, Bullock R, et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 2009; Vol. 72, issue 1:56-62. [: 0028-3878]
45. Patterson JC, Lilien DL, Takalkar A, Pinkston JB. Early detection of brain pathology suggestive of early AD using objective evaluation of FDG-PET scans. International Journal of Alzheimer's Disease 2010; Vol. 2011:ii. [DOI: ; PUBMED: 946590]
46. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology 1999; Vol. 56, issue 3:303.
47. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Archives of Neurology 2001; Vol. 58, issue 12:1985.
48. Petersen RC. Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine 2004; Vol. 256, issue 3:183-94. [: 1365-2796]
49. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, et al. Mild cognitive impairment: ten years later. Archives of Neurology 2009; Vol. 66, issue 12:1447.
50. Quinn TJ, McShane R, Fearon P, Young C, Noel-Storr A, Stott DJ. IQCODE for the diagnosis of Alzheimer's disease dementia and other dementias within a community setting. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: ]
51. Reitsma JB, Glas AS, Rutjes A, Scholten R, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. Journal of Clinical Epidemiology 2005; Vol. 58, issue 10:982. [: 0895-4356]
52. Román GC, Tatemichi TK, Erkinjuntti T, Cummings J, Masdeu J, Garcia JH, et al. Vascular dementia diagnostic criteria for research studies: Report of the NINDS-AIREN International Workshop. Neurology 1993; Vol. 43, issue 2:250. [: 0028-3878]
53. Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Statistics in Medicine 2001; Vol. 20, issue 19:2865-84. [: 1097-0258]
54. Schroeter ML, Stein T, Maslowski N, Neumann J. Neural correlates of Alzheimer's disease and mild cognitive impairment: a systematic and quantitative meta-analysis involving 1351 patients. Neuroimage 2009; Vol. 47, issue 4:1196-206. [: 1053-8119]
55. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia 2011; Vol. 7, issue 3:280-92. [: 1552-5260]
56. Varrone A, Asenbaum S, Vander Borght V, Booij J, Nobili F, Nagren K, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. European Journal of Nuclear Medicine and Molecular Imaging 2009;36:2103-10.
57. Visser PJ, Kester A, Jolles J, Verhey F. Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology 2006; Vol. 67, issue 7:1201-7. [: 0028-3878]
58. Waxman A, Herholz K, Lewis D, Herscovitch P, Minoshima S, Ichise M, et al. Society of Nuclear Medicine procedure guideline for FDG PET brain imaging. Available at www.snm.org-Menu 2009.
59. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al: QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine 2011;155(8):529-36.
60. World Health Organization. Statistical Classification of Diseases and Related Health Problems 9th Revision (ICD-9). 6th Edition. Vol. Hospital edition, vols. 1, 2, 3, Los Angeles, CA: Practice Management Information Corporation (PMIC), 2006.
61. World Health Organization. Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10). Available from apps.who.int/classifications/icd10/browse/2010/en. International (accessed 14th December 2012) 2010.
62. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine 2004; Vol. 256, issue 3:240-6. [: 1365-2796]